93 results
8-K
EX-99.2
WINT
Windtree Therapeutics Inc
18 Apr 16
Amendments to Articles of Incorporation or Bylaws
12:00am
. The Company has also established a presence on Twitter (@Windtreetx) and other social media platforms. The Company intends to use these assets along
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
4 Sep 09
Discovery Labs Announces Date of 2009 Annual Shareholder Meeting
12:00am
responsible for filing all returns and paying any federal, state and municipal income, social security or other tax levied upon or determined with respect
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
5 Dec 22
Other Events
7:48am
with the economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials, clinical trial timelines
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
29 Apr 20
Windtree Therapeutics Announces Reverse Stock Split
5:29pm
current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic
8-K
EX-99.1
fhndc68ejg 15g2m
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-99.2
0hlrelam
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
4fgk5iwdvg 46og5p
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.1
oz4ha
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
16ou9glgefbb1e98
23 Aug 22
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
8:30am
8-K
EX-99.1
2xhv9cl
29 Sep 20
Other Events
7:37am
8-K
EX-99.1
w7dkkft88lreefx3opaj
20 Apr 22
Windtree Announces Positive Topline Results from Its
7:07am
8-K
EX-10.1
rramn
3 Oct 18
Entry into a Material Definitive Agreement
4:41pm
8-K
EX-10.1
y3ka3uncz w5q4b3u
25 Oct 18
Entry into a Material Definitive Agreement
4:27pm
8-K
EX-99.1
gc0jk4nc
13 May 21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
7:34am
8-K
EX-10.1
mb9a1b6jyhr75
28 Oct 19
Entry into a Material Definitive Agreement
4:40pm
8-K
EX-10.1
52nqo
8 Nov 18
Entry into a Material Definitive Agreement
4:20pm
8-K
EX-99.1
eq843bdbu6r3o
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
8-K
EX-10.1
8o32nm9 45prj
23 Nov 18
Entry into a Material Definitive Agreement
4:03pm
8-K
EX-99.1
t3g1lcdhwha6h8j
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm